Peroxisome Proliferator-Activated Receptor-<svg style="vertical-align:-3.366pt;width:11.5125px;" id="M1" height="14.2" version="1.1" viewBox="0 0 11.5125 14.2" width="11.5125"  xmlns="http://www.w3.org/2000/svg">
	<g transform="matrix(1.25,0,0,-1.25,0,14.2)">
		<g transform="translate(72,-60.64)">
			<text transform="matrix(1,0,0,-1,-71.95,64.04)">
				<tspan style="font-size: 17.93px; " x="0" y="0">𝛾</tspan>
			</text>

		</g>
	</g>
</svg> Is a Potent Target for Prevention and Treatment in 
Human Prostate and Testicular Cancer

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="49849.fig.003a" src="https://static.hindawi.com/articles/ppar/volume-2008/249849/figures/49849.fig.003a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>Seminoma</td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="49849.fig.003b" src="https://static.hindawi.com/articles/ppar/volume-2008/249849/figures/49849.fig.003b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>Embryonal carcinoma</td></tr></table></td></tr><tr class="fig-image" id="c"><td><img alt="49849.fig.003c" src="https://static.hindawi.com/articles/ppar/volume-2008/249849/figures/49849.fig.003c.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(c) </b>Yolk sac tumors</td></tr></table></td></tr><tr class="fig-image" id="d"><td><img alt="49849.fig.003d" src="https://static.hindawi.com/articles/ppar/volume-2008/249849/figures/49849.fig.003d.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(d) </b>Choriocarcinoma</td></tr></table></td></tr><tr class="fig-image" id="e"><td><img alt="49849.fig.003e" src="https://static.hindawi.com/articles/ppar/volume-2008/249849/figures/49849.fig.003e.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(e) </b>Teratoma</td></tr></table></td></tr><tr class="fig-image" id="f"><td><img alt="49849.fig.003f" src="https://static.hindawi.com/articles/ppar/volume-2008/249849/figures/49849.fig.003f.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(f) </b>Nomal testis</td></tr></table></td></tr></table>

<table>Representative immunostaining for PPAR-<svg height="12.175" id="M161" style="vertical-align:-3.56265pt" version="1.1" viewbox="0 0 8.6374998 12.175" width="8.6374998" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><path d="M478 372q0 -39 -31 -97t-61 -98t-78 -98q-45 -55 -73 -102q-13 -79 -13 -197q-11 -11 -43.5 -25.5t-53.5 -15.5l-15 17q5 35 26 101.5t47 123.5q8 72 -1.5 174.5t-37.5 178.5q-14 37 -29 37q-20 0 -67 -65l-25 21q37 60 73 90.5t63 30.5q47 0 72 -112q13 -56 17.5 -141.5
t0.5 -143.5h2q155 193 155 297q0 26 -12 47q-5 8 -5 15q0 16 12.5 27t29.5 11q21 0 34 -21t13 -55z" id="x1D6FE"></path></g>
</svg> in testicular tissues samples. A significant strong PPAR-<svg height="12.175" id="M162" style="vertical-align:-3.56265pt" version="1.1" viewbox="0 0 8.6374998 12.175" width="8.6374998" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><path d="M478 372q0 -39 -31 -97t-61 -98t-78 -98q-45 -55 -73 -102q-13 -79 -13 -197q-11 -11 -43.5 -25.5t-53.5 -15.5l-15 17q5 35 26 101.5t47 123.5q8 72 -1.5 174.5t-37.5 178.5q-14 37 -29 37q-20 0 -67 -65l-25 21q37 60 73 90.5t63 30.5q47 0 72 -112q13 -56 17.5 -141.5
t0.5 -143.5h2q155 193 155 297q0 26 -12 47q-5 8 -5 15q0 16 12.5 27t29.5 11q21 0 34 -21t13 -55z" id="x1D6FE"></path></g>
</svg> expression in all testicular cancer (TC) tissues was detected, whereas PPAR-<svg height="12.175" id="M163" style="vertical-align:-3.56265pt" version="1.1" viewbox="0 0 8.6374998 12.175" width="8.6374998" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><path d="M478 372q0 -39 -31 -97t-61 -98t-78 -98q-45 -55 -73 -102q-13 -79 -13 -197q-11 -11 -43.5 -25.5t-53.5 -15.5l-15 17q5 35 26 101.5t47 123.5q8 72 -1.5 174.5t-37.5 178.5q-14 37 -29 37q-20 0 -67 -65l-25 21q37 60 73 90.5t63 30.5q47 0 72 -112q13 -56 17.5 -141.5
t0.5 -143.5h2q155 193 155 297q0 26 -12 47q-5 8 -5 15q0 16 12.5 27t29.5 11q21 0 34 -21t13 -55z" id="x1D6FE"></path></g>
</svg> expression is very weak in normal testis (NT) tissues.</table>

PPAR Research

fig3

Figure 3

Figure 3: Peroxisome Proliferator-Activated Receptor-<svg style="vertical-align:-3.366pt;width:11.5125px;" id="M1" height="14.2" version="1.1" viewBox="0 0 11.5125 14.2" width="11.5125"  xmlns="http://www.w3.org/2000/svg">
	<g transform="matrix(1.25,0,0,-1.25,0,14.2)">
		<g transform="translate(72,-60.64)">
			<text transform="matrix(1,0,0,-1,-71.95,64.04)">
				<tspan style="font-size: 17.93px; " x="0" y="0">𝛾</tspan>
			</text>

		</g>
	</g>
</svg> Is a Potent Target for Prevention and Treatment in 
Human Prostate and Testicular Cancer 

Figure 3 | Peroxisome Proliferator-Activated Receptor-
	
		
			
				𝛾
			

		
	
 Is a Potent Target for Prevention and Treatment in 
Human Prostate and Testicular Cancer 

PPAR Research

Peroxisome Proliferator-Activated Receptor- 𝛾 Is a Potent Target for Prevention and Treatment in Human Prostate and Testicular Cancer

Figure 3

Peroxisome Proliferator-Activated Receptor- Is a Potent Target for Prevention and Treatment in Human Prostate and Testicular Cancer